- ISIN
- US00182C1036
- CUSIP
- 00182C103
- Sector
- Healthcare
- IPO Date
- May 5, 2000
Highlights
- Market Cap
- $1.74B
- Enterprise Value
- $1.77B
- EPS (TTM)
- $4.26
- PE Ratio
- 18.91
- PEG Ratio
- 0.13
- Total Revenue (TTM)
- $923.71M
- Gross Profit (TTM)
- $486.11M
- EBITDA (TTM)
- $234.71M
- Year Range
- $62.61 - $99.50
- Target Price
- $124.00
- ROA (TTM)
- 6.31%
- ROE (TTM)
- 15.95%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
ANIP Performance Chart
ANI Pharmaceuticals, Inc. (ANIP) is up 2.1% since the beginning of the year. At $81 per share, ANIP is trading 19.0% below its 52-week high of $100. Investors who bought $1,000 worth of ANIP shares 5 years ago would now be looking at an investment worth $2,451.
Loading charts...
Returns By Period
ANI Pharmaceuticals, Inc. (ANIP) has returned 2.08% so far this year and 22.91% over the past 12 months. Over the last ten years, ANIP has returned 4.02% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.
ANI Pharmaceuticals, Inc.
- 1D
- 1.37%
- 1M
- -2.59%
- YTD
- 2.08%
- 6M
- -0.17%
- 1Y
- 22.91%
- 3Y*
- 15.92%
- 5Y*
- 19.64%
- 10Y*
- 4.02%
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
ANIP Monthly Returns History
Based on dividend-adjusted daily data since May 5, 2000, ANIP's average daily return is +0.10%, while the average monthly return is +1.58%. At this rate, an investment would double in approximately 3.7 years.
Historically, 50% of months were positive and 50% were negative. The best month was Apr 2001 with a return of +151.3%, while the worst month was Dec 2011 at -79.1%. The longest winning streak lasted 9 consecutive months, and the longest losing streak was 7 months.
On a daily basis, ANIP closed higher 45% of trading days. The best single day was Jun 2, 2000 with a return of +78.6%, while the worst single day was Dec 15, 2011 at -77.4%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 3.69% | -9.71% | 4.06% | 3.32% | -1.18% | 2.64% | 2.08% | ||||||
| 2025 | 6.08% | 5.54% | 8.18% | 5.78% | -17.09% | 11.12% | -2.91% | 47.59% | -2.03% | -1.09% | -6.35% | -6.97% | 42.80% |
| 2024 | 1.23% | 21.23% | 2.16% | -4.53% | -1.67% | -1.88% | 3.20% | -3.00% | -6.42% | -4.05% | -0.03% | -3.41% | 0.25% |
| 2023 | 11.19% | -6.46% | -5.07% | -5.04% | 19.67% | 19.25% | -2.38% | 22.53% | -9.83% | 6.34% | -19.32% | 10.70% | 37.06% |
| 2022 | -12.28% | -7.35% | -24.94% | 4.98% | 2.51% | -1.92% | 15.44% | 7.71% | -12.88% | 20.07% | 8.71% | -4.10% | -12.70% |
| 2021 | -1.72% | 1.96% | 24.19% | -7.91% | 3.22% | 2.04% | -3.20% | -10.61% | 8.21% | 13.89% | 10.06% | 12.01% | 58.68% |
Benchmark Metrics
ANI Pharmaceuticals, Inc. has an annualized alpha of 19.78%, beta of 0.85, and R2 of 0.05 versus S&P 500 Index. Calculated based on daily prices since May 05, 2000.
- This stock participated in 147.49% of S&P 500 Index downside but only 111.33% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.05 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 19.78%
- Beta
- 0.85
- R²
- 0.05
- Upside Capture
- 111.33%
- Downside Capture
- 147.49%
Return for Risk
Risk / Return Rank
ANIP ranks 60 for risk / return — better than 60% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for ANI Pharmaceuticals, Inc. (ANIP) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ANIP | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.38 | ||
| Sortino ratioReturn per unit of downside risk | -1.43 | ||
| Omega ratioGain probability vs. loss probability | 1.15 | 1.37 | -0.22 |
| Calmar ratioReturn relative to maximum drawdown | 0.80 | 2.78 | -1.98 |
| Martin ratioReturn relative to average drawdown | 1.48 | 12.44 | -10.96 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the ANI Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the ANI Pharmaceuticals, Inc. was 98.81%, occurring on Jun 25, 2013. The portfolio has not yet recovered.
The current ANI Pharmaceuticals, Inc. drawdown is 82.09%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2013 bear market2013 | -98.81%Jun 2013 | 13y 23d | — | 26y 24dJun 2000 - now |
Dot-com crash2000–2002 | -18.64%May 2000 | 7d | 6d | 13dMay 2000 - May 2000 |
Drawdown Indicators
| ANIP | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -98.81% | -56.78% | -42.03% |
Max Drawdown (1Y)Largest decline over 1 year | -28.66% | -9.10% | -19.56% |
Max Drawdown (3Y)Largest decline over 3 years | -28.66% | -18.90% | -9.76% |
Max Drawdown (5Y)Largest decline over 5 years | -59.38% | -25.43% | -33.95% |
Max Drawdown (10Y)Largest decline over 10 years | -72.96% | -33.92% | -39.04% |
Current DrawdownCurrent decline from peak | -82.09% | -1.80% | -80.29% |
Average DrawdownAverage peak-to-trough decline | -79.39% | -10.71% | -68.68% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 15.54% | 2.03% | +13.51% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of ANI Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how ANI Pharmaceuticals, Inc. is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for ANIP, comparing it with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, ANIP has a P/E ratio of 18.9. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for ANIP compared to other companies in the Drug Manufacturers - Specialty & Generic industry. ANIP currently has a PEG ratio of 0.1. This PEG ratio is close to the industry average, suggesting the stock’s valuation is balanced against its growth outlook.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for ANIP relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, ANIP has a P/S ratio of 1.8. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for ANIP in comparison with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, ANIP has a P/B value of 3.1. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with ANIP
Add ANI Pharmaceuticals, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with ANIP